Immune Checkpoint Array
4-1BB (TNFRSF9/CD137), CD200 R1, CD40 Ligand (TNFSF5), LAG-3, PD-L2 (B7-DC), B7-H2 (ICOS Ligand), CD27 (TNFRSF7), CD80 (B7-1), OX40 (TNFRSF4), TIM-1 (KIM-1), B7-H3 (CD276), HVEM (TNFRSF14/CD270), CD86 (B7-2), OX40 Ligand (TNFSF4), TIM-3 (KIM-3), B7-H4, CD27 Ligand (TNFSF7), CTLA-4 (CD152), PD-1, CD200, CD28, ICOS, B7-H1 (CD274/PD-L1)
Serum, Plasma, Cell Culture Supernatant, Cell Lysates, Tissue Lysates
Multiplex Protein Detection
Incubate with Sample
Incubate with Biotinylated Detection Antibody Cocktail
Incubate with HRP-Conjugated Streptavidin
Incubate with Detection Buffers
Image with chemiluminescent imaging system
Perform densitometry and analysis
Antibody Array Membrane
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Once thawed, please keep reagents under suitable conditions respectively. Do not use past expiration date.
Immune checkpoint is a kind of signal for regulating the antigen recognition of T cell receptor (TCR) in the process of immune responce. Immune checkpoint contains two kinds of signals: (1) Co-stimulatory immune checkpoint: stimulating immune progress, such as CD28, ICOS, and CD137; (2) Co-inhibitory immune checkpoint: inhibiting immune progress, such as PD1, CTLA-4, and VISTA. When immune system is attacking pathogens, these immune checkpoint molecules can protect the normal tissues from damage. The cancer cells cleverly escape from immune attack by dysregulating immune checkpoint related proteins. Immune checkpoint therapy relys on functioning immune system with agonists of co-stimulatory signals or antagonists of inhibitory signals.